Teva’s Ajovy Failure In Cluster Headaches Good For Lilly’s CGRP Inhibitor Emgality
Executive Summary
Lilly's Emgality looks set to benefit from Teva ending clinical development of its CGRP antibody competitor in cluster headaches due to lack of efficacy in Phase III.